- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Ceribell Names Joshua Copp as Chief Operating Officer
Copp comes to the company from McKinsey & Co.
Ceribell announced that it has named Joshua Copp as its new chief operating officer.
In a press release, Ceribell co-founder and CEO Jane Chao, PhD, said, “Joshua's leadership within McKinsey & Co.'s Medical Device Division provides him with a wealth of expertise that he will now bring to our team. His professional experience driving growth and shaping markets with clients aligns seamlessly with Ceribell's vision to make Ceribell the standard of care in seizure management."
Ceribell developed an AI-powered point-of-care EEG diagnostic system and is working to improve seizure management in acute care.
"Ceribell stands at the forefront of medical technology, reshaping the landscape of neurodiagnostics," said Joshua Copp in the press release. "I look forward to working alongside this innovative team to enable hospitals to optimize workflows and save lives."
Source
(Oct. 2, 2023); Ceribell Inc.; Ceribell Appoints Joshua Copp as Chief Operating Officer; https://www.prnewswire.com/news-releases/ceribell-appoints-joshua-copp-as-chief-operating-officer-301943415.html
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
